Olema Oncology, Inc. (OLMA) stock
OLMANasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.06−0.16 (-2.22%)
Close on Nov 18, 2026Market cap $617.73MP/E –Yield –
Olema Oncology operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Olema Oncology's operating income for the twelve months ending Jun 30, 2026 was -$221.13M. For fiscal 2025 it was -$178.70M. The highest annual figure on record is -$4.32M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$178.70M | – |
| FY2024 | Dec 31, 2024 | -$142.26M | – |
| FY2023 | Dec 31, 2023 | -$104.96M | – |
| FY2022 | Dec 31, 2022 | -$106.99M | – |
| FY2021 | Dec 31, 2021 | -$71.49M | – |
| FY2020 | Dec 31, 2020 | -$21.53M | – |
| FY2019 | Dec 31, 2019 | -$4.32M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$67.18M | – |
| Q1 FY2026 | Mar 31, 2026 | -$57.99M | – |
| Q4 FY2025 | Dec 31, 2025 | -$50.08M | – |
| Q3 FY2025 | Sep 30, 2025 | -$45.88M | – |
| Q2 FY2025 | Jun 30, 2025 | -$47.86M | – |
| Q1 FY2025 | Mar 31, 2025 | -$34.87M | – |
| Q4 FY2024 | Dec 31, 2024 | -$36.77M | – |
| Q3 FY2024 | Sep 30, 2024 | -$37.62M | – |
| Q2 FY2024 | Jun 30, 2024 | -$33.53M | – |
| Q1 FY2024 | Mar 31, 2024 | -$34.34M | – |
| Q4 FY2023 | Dec 31, 2023 | -$30.42M | – |
| Q3 FY2023 | Sep 30, 2023 | -$23.34M | – |
| Q2 FY2023 | Jun 30, 2023 | -$21.60M | – |
| Q1 FY2023 | Mar 31, 2023 | -$29.60M | – |
| Q4 FY2022 | Dec 31, 2022 | -$27.22M | – |
| Q3 FY2022 | Sep 30, 2022 | -$23.22M | – |
| Q2 FY2022 | Jun 30, 2022 | -$33.29M | – |
| Q1 FY2022 | Mar 31, 2022 | -$23.25M | – |
| Q4 FY2021 | Dec 31, 2021 | -$21.76M | – |
| Q3 FY2021 | Sep 30, 2021 | -$17.76M | – |
| Q2 FY2021 | Jun 30, 2021 | -$16.52M | – |
| Q1 FY2021 | Mar 31, 2021 | -$15.45M | – |
| Q4 FY2020 | Dec 31, 2020 | -$10.13M | – |
| Q3 FY2020 | Sep 30, 2020 | -$7.87M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.49M | – |
| Q1 FY2020 | Mar 31, 2020 | -$1.04M | – |
See a number that looks wrong?